Trial Profile
Levodopa in EArly Parkinson's disease: A prospective, randomized, double blind, placebo-controlled, delayed start trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Oct 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms LEAP
- 16 Sep 2020 Results of post-hoc analyses presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 24 Jan 2019 Primary endpoint has not been met. (Difference in the mean total Unified Parkinsons Disease Rating Scale (UPDRS) scores between the early and delayed groups at 80 weeks)
- 24 Jan 2019 Results (n=446) published in the New England Journal of Medicine